Genetic Surveillance of SARS-CoV-2 M pro Reveals High Sequence and Structural Conservation Prior to the Introduction of Protease Inhibitor Paxlovid
2022; American Society for Microbiology; Volume: 13; Issue: 4 Linguagem: Inglês
10.1128/mbio.00869-22
ISSN2161-2129
AutoresJonathan T. Lee, Qingyi Yang, Alexey V. Gribenko, B. Scott Perrin, Yuao Zhu, Rhonda D. Cardin, Paul Liberator, Annaliesa S. Anderson, Li Hao,
Tópico(s)vaccines and immunoinformatics approaches
ResumoThe recent authorization of oral severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) antivirals, such as Paxlovid, has ushered in a new era of the COVID-19 pandemic. The emergence of new variants, as well as the selective pressure imposed by antiviral drugs themselves, raises concern for potential escape mutations in key drug binding motifs.
Referência(s)